Collectively, our findings highlight EGFR–STAT3 activation as a novel ETV1‐regulated oncogenic pathway, providing a rationale for repurposing EGFR inhibitors in combination with STAT3 inhibitors as a therapeutic strategy for the 8–10% of prostate carcinomas characterized by ETV1 rearrangements/overexpression. Here, ETV1 is linked to prostate carcinoma.